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Abstract 33 
The aim of this research was to explore consumer perceptions of personalised nutrition 34 
and to compare these across three different levels of “medicalization”: lifestyle 35 
assessment (no blood sampling); phenotypic assessment (blood sampling); genomic 36 
assessment (blood and bucal sampling). The protocol was developed from 2 pilot focus 37 
groups conducted in the UK. Two focus groups (one comprising only “older” individuals 38 
between 30-60 years old, the other of adults 18-65 years of age) were run in the UK, 39 
Spain, the Netherlands, Poland, Portugal, Ireland, Greece and Germany (N=16). The 40 
analysis (guided using grounded theory) suggested that personalised nutrition was 41 
perceived in terms of benefit to health and fitness and that convenience was an 42 
important driver of uptake.  Negative attitudes were associated with internet delivery 43 
but not with personalised nutrition per se. Barriers to uptake were linked to broader 44 
technological issues associated with data protection, trust in regulator and service 45 
providers. Services that required a fee were expected to be of better quality and more 46 
secure. An efficacious, transparent and trustworthy regulatory framework for 47 
personalised nutrition is required to alleviate consumer concern. In addition, developing 48 
trust in service providers is important if such services to be successful.  49 
Keywords Personalised nutrition; Nutrigenomics; Consumer; Qualitative; Barriers; 50 
Acceptance; Focus group; Food4Me. 51 
Introduction 52 
There is evidence that healthy dietary choices may contribute to a substantial reduction 53 
in disease incidence (Nishida et al., 2004) and it has been estimated that 54 
approximately 80% of cases of cardiac disease, stroke, type 2 diabetes, and 40% of 55 
cancers could be avoided through improved lifestyle choices, including those related to 56 
diet (WHO 2011). There may be considerable variation between individuals in what 57 
constitutes an optimal diet and, to some extent, these differences may be genetically 58 
determined (Madden et al., 2011). 59 
 60 
Currently, nutritionists and dietitians personalise nutritional advice based on age, sex, 61 
body mass index (BMI), diet, physical activity and clinical picture (Boland, 2008). Such 62 
a strategy does not take account of genetic differences which may interact with 63 
phenotype and co-determine health impacts of dietary choices. A possible health 64 
promotion strategy may be to employ personalised nutrition (PN), which takes account 65 
of genetic differences between individuals, including how certain genes affect the risk 66 
of diet-related diseases (Kaput & Rodriguez, 2004) and various (primarily internet 67 
based) services are currently being offered commercially (Ronteltap et al., 2012).  68 
 69 
Societal responses to the application of various technologies in the food sector have 70 
tended to attract greater controversy compared to applications of the same technology 71 
in medicine or some other non-food areas (Frewer et al., 2011). Societal negativity has 72 
frequently been driven by risk perceptions, such that technologies that are perceived to 73 
be risky, unnatural and uncontrollable are more likely to be rejected by the public 74 
(Fischhoff et al.,1978; Slovic, 1992). Many empirical investigations have focused on 75 
consumer perceptions about food technologies (Bredahl, 2001; Miles & Frewer, 2001; 76 
Sparks & Shepherd, 1994), where consumer rejection of applications is typically high. 77 
In the case of PN and nutrigenomics (the study of how different foods may interact with 78 
specific genes to increase the risk of common chronic diseases), consumers may 79 
perceive the application to be more closely linked to medicine than to food, and thus 80 
tolerate greater perceived risk and unnaturalness, as the benefits may also be 81 
perceived to be greater (Ronteltap et al., 2008; Ronteltap et al., 2007). Individual 82 
reactions to innovations in the food sector may be more favourable if associated with 83 
tangible and personally relevant health benefits (Costa-Font & Mossialos, 2007; 84 
Schenk et al., 2008). Stewart-Knox et al. (2008) surveyed more than 6000 consumers 85 
about their attitudes to nutrigenomics across six European countries, and found that 86 
individuals who were aware that they had health problems associated with the 87 
metabolic syndrome appeared particularly favourable toward nutrigenomics-based 88 
interventions. Similarly, Pin (2009) reports that if personalised nutrition was perceived 89 
to benefit individuals, the consequences were perceived as more desirable which was 90 
associated with strengthened intentions about taking a test and adopting a diet. From 91 
this, it may be predicted that the more benefits (or risks) a person perceives to be 92 
potentially derived from adoption of PN, the more positive (or negative) they will feel 93 
about adopting it. In addition, cultural and social aspects of food and food choices vary 94 
(Lennernäs et al.,1997), and may influence adoption of PN (Pin & Gutteling, 2008; Pin 95 
et al., 2008).  An important element of consumer/citizen acceptance of potentially 96 
controversial technologies is that of trust, which may vary across different socio-97 
historical contexts (Frewer et al., 2011). Trust may refer to the governance and 98 
regulatory systems put into place to optimise consumer protection (Van Kleef et al., 99 
2006), or to information providers delivering information about PN, as well as to those 100 
organisations and businesses delivering services. Various researchers have examined 101 
the impact of different types of citizen/consumer trust associated with technological 102 
innovation, as well as its impact on other potentially influential determinants of 103 
technology acceptance (inter alia van Kleef et al., 2006, Slovic et al., 2005). Trust in 104 
information sources and opinion leaders may be particularly influential under 105 
circumstances where attitudes are as yet inchoate, in particular in relation to the 106 
formation of shared values (Fischer et al., in press). Generally, trust in scientific 107 
governance has increased across Europe in recent years (Gaskell et al., 2011). In the 108 
case of PN, trust in regulators, governance structures more generally, and service 109 
providers may influence acceptance, particularly in relation to genetic testing, where 110 
data storage and protection emerge as particularly salient issues (Castle & Ries, 2007). 111 
Ethical, social and data protection questions associated with PN must be addressed 112 
(Rimbach & Minihane, 2009in the context of direct-to-consumer genetic testing 113 
(Hogarth et al., 2008).. Various psychological and contextual barriers to uptake of PN 114 
may be identified (Ronteltap et al., 2009). For example, higher levels of perceived self-115 
efficacy and control (Armitage & Conner, 1999), or regulatory focus (Sengupta & Zhou, 116 
2007), may influence uptake. Concerns about privacy and data security may be 117 
relevant (Castle & Ries, 2007) and this may become more salient as the level of 118 
biometric data required for PN “assessment” is increased.  119 
 120 
The aim of the research was to explore European citizens’ perspectives, attitudes, 121 
opinions, concerns and beliefs in relation to PN, as well as identify consumer priorities 122 
and preferences regarding provision of PN information and services.  123 
 124 
Methods 125 
Focus groups were used for generating data on the basis of their capacity to provide 126 
insights into participants’ perceptions of, and attitudinal consistency associated with, 127 
substantive issues that arise from both individual contributions and interactive 128 
exchanges (Barbour, 2007). The use of focus group methodology facilitated exploratory 129 
analysis in the hitherto not well understood area of public opinion towards PN.  130 
 131 
Data exploring European consumers’ attitudes and opinions towards PN were collected 132 
in eight European countries: Ireland, University College Dublin (IE); United Kingdom, 133 
University of Reading (UK); Spain, University of Navarra (ES); Greece, Harokopio 134 
University Athens (GR); The Netherlands, Wageningen University (NL); Germany, 135 
Technical University Munich (DE); Poland, National Food and Nutrition Institute (PL); 136 
and Portugal, University of Porto (PT). (As a different sampling profile for the focus 137 
group recruitment was used in Norway, these data will be reported separately). Country 138 
codes are adopted from ISO 3166. Ethical approval for the research was obtained by 139 
each participating institution. 140 
 141 
Focus Group Protocol 142 
To ensure internal consistency in the research approach across the eight contributing 143 
countries, a standardised focus group protocol (including focus group composition) was 144 
developed by a core of qualitatively experienced researchers from Ulster, Newcastle, 145 
Wageningen and Porto. Following ethical approval, two pilot focus groups were 146 
conducted in Newcastle during September 2011 in English, and the results used to 147 
further refine the protocol. Pilot data were not further used in the main analysis to 148 
ensure all data had been collected using an identical protocol. About one month prior to 149 
the focus groups being held (October 2011), a two day training course was provided to 150 
harmonise focus group moderation in participating centres. The research protocols 151 
were translated from English into the national languages of the centres responsible for 152 
the data collection and back-translated to ensure consistency in methodology was 153 
applied across all the centres.  154 
 155 
Participants 156 
One hundred and twenty six participants were recruited using social research agencies 157 
(UK, Spain, the Netherlands, Poland and Portugal) or through distributed flyers and/or 158 
posters displayed in public fora (Ireland, Greece and Germany). Two focus groups 159 
were conducted in each country. Each focus group comprised 6-10 free living, urban 160 
dwelling participants of a mix of sex and occupations within the groups. Individuals who 161 
were not healthy (according to their own definition) were excluded. Vulnerable 162 
individuals, health professionals with an interest in food or diet, individuals with a 163 
background in genomics, nutrigenomics or personalised medicine, individuals who had 164 
previously taken part in research related to PN, or those who were regular focus group 165 
attendees were excluded. In each centre, one group comprised a mixed age profile 166 
(18-65), and one group comprised “older” individuals (30-65), to allow age or cohort 167 
specific issues to be investigated. Participant profiles were verified using a 168 
questionnaire administered to record sex, age, marital status, household size, number 169 
of dependents, and information about occupation, before the focus groups commenced 170 
(Table 1).  171 
There were no significant differences in the distribution of sex (X²=0.40, df=7, p=1.00) 172 
or age group (X²=38.85, df=35, p=0.30; Monte Carlo approximation). Marital status did 173 
differ across countries, with Germany and Greece having more, and the Netherlands 174 
and Poland fewer, single individuals than expected (X²=14.98, df=7, p=0.03; Monte 175 
Carlo approximation). 176 
……………………. 177 
Insert Table 1 here. 178 
……………………. 179 
 180 
Procedure 181 
Following ethical approval, the main data collection phase occurred during November 182 
2011, following the protocol to ensure a uniform procedure across all centres. Focus 183 
groups were held at convenient, neutral and private locations. Upon arrival, the 184 
participants were given a financial reimbursement of £30/€30 to cover time and travel 185 
expenses. Informed consent was obtained and the profile questionnaire administered. 186 
The discussions followed the protocol outlined in a semi-structured discussion guide 187 
(Table 2). The topic list included a general introduction/ warm up session focussing on 188 
the participants’ interest in health and food (based on 2 open-ended questions included 189 
at the end of the profile questionnaire). Following this, participants’ awareness and 190 
spontaneous understanding of PN were explored. Participants were then asked to 191 
reflect upon the following definition “PN is healthy eating advice that is tailored to suit 192 
an individual based on their own personal health status, lifestyle and/or genetics”. The 193 
discussion moved onto three PN scenarios that sequentially introduced increasing 194 
levels of medicalization. No other information was provided. 195 
………………….. 196 
Insert Table 2 here 197 
…………………… 198 
 199 
Scenario 1 related to the provision of ‘lifestyle’ related data in which participants were 200 
asked to imagine and comment on a scenario where they wanted to change their diet 201 
to improve health through an on-line provider who requested the following information: 202 
name and e-mail address, gender, age, height, weight, food allergies and intolerance, 203 
own medical history, eating habits and physical activity levels. 204 
 205 
Scenario 2 related to the provision of ‘phenotypic’ data in which participants were 206 
asked to provide supplementary data to Scenario 1 that included a home kit to collect 207 
information regarding waist and hip measurements and nutrient level from a finger prick 208 
blood test. The participants were shown an instruction leaflet on a prompt board 209 
describing how to take the blood samples (providing five blood spots on a card, which, 210 
once dry, was packaged and posted to the service provider). 211 
 212 
Scenario 3 related to the provision of ‘genotypic’ data where in addition to the 213 
information supplied in scenario 1 and the blood spots in scenario 2, participants were 214 
asked to provide genetic information which could be obtained via a home kit using a 215 
cotton bud to collect buccal cells from the inside of the cheek. Information on the 216 
collection and packaging of this information was presented as above. 217 
 218 
Ethical, legal and social issues that had not been spontaneously mentioned during the 219 
focus groups were then prompted or clarified. Finally, the discussion focussed on the 220 
future of PN services. Participants were then thanked and debriefed. The focus groups 221 
each lasted approximately 1.5 hours, were audio-recorded, subsequently transcribed 222 
verbatim, anonymised and (where appropriate) translated into English for analysis. 223 
Data Analysis 224 
The analysis followed a thematic approach (Gibbs, 2007). Preliminary data analysis 225 
was conducted by four analysts from the universities of Ulster and Newcastle. First, the 226 
analysts independently read, manually coded and annotated all 16 transcripts. The 227 
coding followed an inductive approach best suited to the exploratory nature of the 228 
research questions (Strauss & Corbin, 1998). Based on annotations and key codes, 229 
response? patterns or themes were identified within and across the transcripts to form 230 
an initial coding scheme (Denzin & Lincoln, 1994). The themes were discussed and a 231 
thematic framework developed, which was further refined by multiple analysts 232 
independently coding small passages of text and then comparing and discussing 233 
coding decisions. After several iterative refinements, a sufficiently robust coding 234 
scheme was established, indicated by agreement in the coding of small passages by 235 
multiple analysts reaching acceptable inter-coder reliability (Cohen’s kappa=0.67; 236 
Landis and Koch, 1977). Subsequently, all 16 transcripts were coded in detail by a 237 
single analyst using NVivo9 (QSR International Pty.). A thematic analysis of the coded 238 
transcripts was conducted by analysts from Ulster and Newcastle Universities.  239 
 240 
Results 241 
Sample Description 242 
Demographic composition was similar across focus groups and countries (Table 1). 243 
The average proportion of males to females was 46/54% the majority of whom (66.5 %) 244 
were married. The average proportion in each age category for focus group 1: 18-25 245 
yrs = 21%; 26-30 yrs = 9.5%; 31-39 yrs = 20%; 40-49 yrs = 21%; 50-59 yrs =18%; 60-246 
65 yrs =13%; and, for focus group 2 (older): 18-25 yrs = 0%; 26-30 yrs = 2%; 31-39 yrs 247 
= 24%; 40-49 yrs = 31%; 50-59 yrs = 22.5%; 60-65 yrs =16%.The percentage of 248 
households who had children in focus group 1: 60%; 25%; 72%; 50%; 63%; 100%; 249 
57%; 43%; and, for focus group two: 60%; 38%; 50%; 87%; 50%; 86%; 57%; 67%. 250 
 251 
The results are presented in sections relating to the awareness and characterisations 252 
of PN; categories of potential PN users; discourses underpinning a PN service; and, 253 
specific concepts relating to the online delivery of a PN service. The themes reported 254 
arose in all countries included in the research.  255 
Awareness and Characterisation of PN 256 
Participants' expectations of the types of information required to support PN advice 257 
largely mirrored lifestyle assessment data (scenario 1). Awareness of PN that includes 258 
phenotypic (scenario 2) and genotypic data (scenario 3) was low by comparison. 259 
Although this suggests that people may require educative explanations of PN at higher 260 
levels of medicalization, the term 'personalised nutrition ' appeared to have an intuitive 261 
logic: 262 
‘...it’s designed to work within your lifestyle, to keep you at an optimum weight, [….] 263 
keep your body functioning properly. At the end of the day it’s kind of designed around 264 
you rather than a generalisation.’ (UK). Participants likened a PN service to existing 265 
forms of individualised advice related to food, diet, and lifestyle, e.g. ‘personal 266 
coaches’, ‘nutrition counsellor or trainer’ and ‘nutrition consultant’. Conceptually, PN 267 
was perceived as being beneficial with a variety of potential users. 268 
 269 
Potential PN Users 270 
Three categories of potential PN user were inductively derived from the data and 271 
classified according to primary motivating factors for using PN: 1) Health management 272 
(disease prevention, particularly where there was genetic foreshadowing of chronic 273 
illness, or the alleviation of symptoms associated with pre-existing health conditions): 274 
‘I think that diet is not only for being slim, diet is health, because there’s a lot of 275 
lean people with very high cholesterol ... or intolerance to certain foods...’ (ES).  276 
Weight reduction to improve health outcomes (rather than improve appearance) was 277 
characteristic of this category. 2) Personal appearance – through changing or 278 
perfecting body morphology via weight loss, weight gain or for aesthetic reasons such 279 
as body building. 3) Athletic performance - to improve fitness and competitive 280 
performance of ‘committed athletes’ such as marathon runners or cyclists.  281 
‘I think it would be athletes…, maybe because they’re … not necessarily 282 
wanting to lose weight but just to optimise how your […] body’s running …( UK) 283 
Motivations for PN use were, therefore, broader and more nuanced than health alone 284 
and were recognised to be dependent on personal commitment to dietary change. A 285 
lack of will power was recognised as a barrier to PN. 286 
‘It still comes down to willpower as well, the individual. You can have the best diet 287 
going but if you haven’t got the willpower to stick to it’ (UK) 288 
  ‘...you can arrange your life accordingly, but it takes a lot of will power to do that’ 289 
(GR) 290 
 291 
Participants identified further factors which might act as barriers to PN dietary changes 292 
including a dislike of recommended foods, reduced food choices and making multiple 293 
meals for different household members. 294 
 295 
Personal Nutrition Service Discourses 296 
Analysis of participant interpretations of a PN service revealed three thematic 297 
discourses associated with the concept of 'personal'. These include the relationships 298 
between 1) personal nutrition and personal contact; 2) personal contact and 299 
professional contact; and, 3) personal and private. These discourses underpin an 300 
understanding of attitudes to the on-line delivery of a PN service. 301 
 302 
Personal nutrition = personal contact 303 
Personal nutrition was suggestive of personal contact and the requirement for personal 304 
contact increased with successive levels of medicalisation. Face-to-face contact 305 
implied practical and emotional benefits. At a practical level, it denoted a perceived 306 
efficiency in assessing individual health status. This was revealed when participants 307 
compared the passive, on-line provision of health-related information to that provided 308 
by a health professional whose tacit knowledge and expertise could result in 309 
spontaneous and reactive interactions:  310 
‘...it can’t be...tailored for me because that much information can’t be in a 311 
questionnaire, I guess. What’s balancing when you meet someone face-to-face 312 
for 15 minutes and who gets to know me, no questionnaire can compensate for 313 
this...’ (DE) 314 
‘For me it’s important that there’s the presence of a professional who examines 315 
me...because face to face is important, to see one’s symptoms, and all that...’ 316 
(ES) 317 
Medical expertise was also considered important for assisting with or supervising the 318 
effective taking of blood and saliva samples, particularly where people doubted their 319 
own competency or self-efficacy: 320 
‘To be honest I think that doing these tests this way isn’t very feasible...I think it 321 
had to be a professional to do them….’‘ (PT) 322 
‘I'm not an expert and I would give wrong results”. (GR) 323 
Personal contact provided emotional support, encouragement and the motivation to 324 
follow a PN dietary plan. Such activities, that reduced the risk of failure, were also 325 
interpreted as ‘care’: 326 
 ‘someone to check...such as an instructor who takes care of us’ (PL)  327 
‘...a confirmation of like, am I doing OK?’ (NL) 328 
Personal contact = professional contact 329 
Personal contact was associated with appropriately qualified medical or nutrition 330 
professionals. ‘Professionals’ were associated with perceptions of trust in the taking of 331 
bio-samples and their handling and processing.  332 
‘...if you give it to a general practitioner, then you know where it’s going’ (NL) 333 
 ‘…the nearest clinic it would be possible to take the test without worry about who 334 
does it and where’ (PL)  335 
 336 
Personal = private and protected 337 
An issue which emerged in the PN discourses centred on keeping personal data 338 
private and protected. Some participants expressed concerns related to the invasion of 339 
privacy and data security which increased with PN level. The linking of personal with 340 
biological data was of particular concern: 341 
‘... information that is really personal, like DNA, […] – as long as it doesn’t 342 
escape’ (DE) 343 
‘If there’s no connection with surname ... phone number [….] I think I would prefer 344 
not to put all that there’ (PL) 345 
A key personal strategy to protecting privacy was participant anonymity. This included 346 
a reluctance to supply names and addresses with personal data from lifestyle to 347 
genotypic. Concerns about privacy and data protection were accentuated when 348 
associated with an on-line PN service delivery format. 349 
 350 
 On-line PN Service Delivery: Perceived Risks and Benefits 351 
During initial PN discussions, participants assumed that PN services would be provided 352 
through existing health service provision. 353 
 ‘I think that it will have to be in the healthcare sector’ (IE) 354 
‘so maybe either the National Health Fund could run it ... right?’ (PL) 355 
This assumption provided a counterpoint to the perceived characteristics of on-line 356 
commercial PN service providers (Table 3). Perceived lack of self-efficacy in providing 357 
blood and buccal samples, and data protection, was amplified when participants 358 
considered an on-line method of PN service delivery. Trust was a defining concept 359 
underpinning concerns associated with the extended PN service chain, relating to, for 360 
example, the credibility and expertise of PN service staff; accountability and 361 
transparency in data management; and, the transport of bio-samples. Perceived 362 
benefits associated with an on-line PN service related to privacy and relationship 363 
building.  364 
 365 
Credibility of On-Line PN Staff 366 
It was considered important that the PN provider website displayed their professional 367 
qualifications and credentials in order for on-line providers to be perceived as legitimate 368 
or credible; 369 
‘……[...]how, how accurate are they, how robust are they, you know what level 370 
of expertise is there, […]there’s no qualification behind what you’re reading….’ ‘I 371 
suppose it would depend who I was dealing with and who was the name behind 372 
it. You don’t know who these people are [...]anybody can set up a website...’ 373 
(UK) 374 
‘The first thing I’d so is to have information about whose behind all this.’ (ES) 375 
 376 
Personal Contact - a Perceived Need 377 
Although some participants expressed a preference for anonymity, it was deemed 378 
important that professionals were ‘easily’ available to provide assistance, even if they 379 
were not contacted. The framing of personal contact in terms of ‘difficult’ and ‘easy’ are 380 
indicative of the potential barriers and facilitators to interacting on-line:  381 
‘It would be difficult to see how it be personalised if it is just an electronic 382 
relationship’ (IE) 383 
‘I think that might be more difficult, because you’re talking to a machine. And get 384 
answers on that and communicating like that, is harder for me, than when I’m 385 
talking directly to someone if you have a problem....’ (NL) 386 
 387 
Continuity of Care and Relationship Building 388 
Continuity of care was considered essential in a PN service. Participants expressed a 389 
preference for advice and support to be delivered by the same professional. A critical 390 
issue appeared to be relationship building within the on-line environment. In relation to 391 
this, participants suggested extending communication interactions through a variety of 392 
on-line media and dedicated telephone lines: 393 
‘... your personal assistant...to watch you during your participation in this 394 
program...to have the same person...to know that I’m talking to my doctor’ (GR)  395 
‘or some info line that you can ring up...’(PL) 396 
Test Anxiety and Feedback Support  397 
Irrespective of whether in person or through other means, support was considered 398 
essential to overcoming barriers relating to competency and self-efficacy associated 399 
with the taking of blood and cheek cell samples at higher levels of PN medicalisation. 400 
There was an expectation that high levels of support would accompany feedback to 401 
reduce anxiety relating to phenotypic and genotypic results: 402 
 ‘A place where there is an address and a telephone number that you can 403 
investigate’ (NL)  404 
‘There should be something... when you realize, after your own experimental 405 
period, I can deal with this or not. Or with this and this aspect I can deal or not’ 406 
(DE) 407 
 408 
Accountability in Data Management 409 
A commercially based delivery system was perceived to carry specific risks to users. 410 
Foremost was the notion that the website would sell personal data for commercial gain, 411 
or that personal data could be fraudulently ‘hacked’. 412 
 ‘you simply don’t know about what happens with your data’ (DE)  413 
‘for example, impersonated or someone hacked in’ (PL) 414 
 415 
Anonymity 416 
A perceived advantage of on-line PN service delivery was that the process, if properly 417 
regulated, had the potential to afford greater privacy than that delivered off-line:  418 
‘If you get on the internet you don’t have to, like make yourself known’ (NL) 419 
‘Because you want to keep something personal... (GR) 420 
Some discussants implied that they may be more likely to use on-line PN if the process 421 
were anonymised:  422 
‘ Is it anonymous (PT)  423 
 ‘I might do it, if it would be like, anonymous, if you don’t have to register...’ (DE) 424 
 425 
Transparency and Trustworthiness of Handling Bio-Samples 426 
The perceived inadequacy and lack of trust in postal services to reliably handle and 427 
deliver biological samples effectively, safely and securely emerged as an issue in all 428 
focus groups. Some of these concerns were experientially based.  429 
 ‘when it goes by post, no one’s going to carry it like an egg, it could get broken, 430 
damaged, whatever’ (PL)  431 
‘just the other day there was this story about mailmen not delivering like half of 432 
the mail or ...it ends up in the ditch or in a container’ (NL)  433 
Strategies to allay concerns about the transfer of samples (at genotype and phenotype 434 
levels) included registered mail and courier services  435 
 436 
Paying for PN 437 
Participants related price to the quality of commercial PN services. Payment for PN 438 
was associated with a greater likelihood of achieving the benefits sought, data 439 
protection measures being in place, and increased probability of qualified individuals 440 
being employed at the service end. Payment for the service provided a form of 441 
validation, symbolised the quality of provision and provided a contractual and thus legal 442 
right to redress:  443 
‘... if it’s cheap, we also think it will not be good...’ (SP) 444 
‘... if you do not pay, then you have services of doubtful quality’ (GR) 445 
Willingness to pay was related to benefit perceptions. Those who were unwilling to pay 446 
tended not to perceive any added value of PN above those services provided by a GP.  447 
‘If it is really about your health, then yes...I think it’s a good idea to pay for it’ (NL)  448 
‘Health was not for sale’ (PL) 449 
However, genetic test results were deemed worthy of payment by others . 450 
 ‘I’d be prepared to pay a bit more (genotype level)...’ (IE). 451 
‘for this kind of stuff you have to pay because otherwise it wouldn’t be trustworthy 452 
at all’ (NL) 453 
 454 
…………………….. 455 
Insert Table 3 here 456 
……………..……… 457 
 458 
Discussion  459 
There was little evidence of consumer rejection of the concept of PN per se. Negative 460 
perceptions appeared to be linked to the process of engagement with the technology, 461 
e.g. relating to storage of data, or trustworthiness or expertise of commercial 462 
companies. Consumer negativity towards food technologies is associated with greater 463 
perceptions of unnaturalness, catastrophic potential and involuntary exposure. In the 464 
case of PN, consumers are not, at least in the context of the present study, being 465 
asked to consume “unnatural” or novel foods, in particular those developed using novel 466 
technologies, but rather are asked to select, from those foods currently available, those 467 
which are the most appropriate for their individual or genetic profiles. While the use of 468 
human DNA to identify appropriate nutritional profiles may be regarded as a 469 
technological advance, it may be perceived as a medical application and, therefore, 470 
more “necessary”. In terms of involuntary exposure, adoption of PN is perceived as a 471 
matter of personal choice. There was no evidence of concerns regarding potentially 472 
catastrophic effects, where many people are negatively affected by the occurrence of 473 
an event. It is difficult to identify potentially catastrophic impacts of PN other than those 474 
associated with the loss of large quantities of personal data, which could be misused if 475 
they fell into the wrong hands.  Discussants provided concrete expression of the 476 
potential benefits of genetic testing in general, and of PN in particular, for individual and 477 
public health. Future research may consider whether such benefits are traded off 478 
against perceived risk at the technological delivery interface. Similar results have been 479 
reported elsewhere (Ronteltap et al., 2009, genetic testing in both Rose et al., 2005; 480 
Bates et al., 2005; Catz et al., 2005, Skirton et al., 2006).  481 
However, related to risk perception is the concept of “optimistic bias”, where an 482 
individual judges that negative events are less likely to affect the person making the 483 
judgement in comparison to the risks experienced by an average member of society 484 
(Miles & Scaife, 2003; Weinstein, 1989). Discussants identified individuals who might 485 
benefit from PN (for example, those wanting to improve health or athletic importance, 486 
or reduce weight), who were also at risk from unhealthy eating practices. There was 487 
less evidence to suggest that discussants themselves would adopt PN, as it was 488 
perceived to apply to others who were at “greater risk”. This might operate as a barrier 489 
to improved public health through PN in the future, unless communication about 490 
benefits can be targeted to those individuals with potential to benefit specifically from 491 
its application.  492 
 493 
A potentially influential issue which emerged from the data related to trust (see also 494 
Saba & Messina, 2003; Williams & Hammitt, 2001). Under circumstances where 495 
knowledge about an issue is limited, people tend to rely more strongly on risk 496 
managers to protect consumer health (Siegrist & Cvetkovich, 2000). Discussants 497 
tended to be more comfortable with nutrigenomics being provided by health 498 
professionals, in particular those working in the public sector, who are not motivated by 499 
financial gain. Van Kleef et al. (2006) have suggested that trust is increased if the 500 
“responsible authorities” engage in effective risk management activities which prioritise 501 
consumer protection over and above the economic interests of particular institutions or 502 
industries. Identification of a “named individual” to provide nutrigenomics advice, who is 503 
perceived to be interested in health rather than motivated by financial incentives, with 504 
associated authentication and/or certification, appears also to increase trust in the 505 
service.  506 
 507 
Ethical issues raised did not appear to differ from those associated with genetic 508 
technologies generally. Most concerns appeared to focus on anonymisation of stored 509 
personal data (in particular relating to genetic information) and potential misuse of such 510 
data by companies or through fraudulent acquisition. Developing ethically appropriate 511 
and societally acceptable guidelines for medical applications of genetic technologies 512 
(Knoppers & Chadwick, 2005) will allay ethical concerns about the development and 513 
application of nutrigenomics. Concerns about data security might be alleviated by 514 
displaying evidence that the service is authentic and providing a guarantee of data 515 
protection. Implementing consumer protection regulation about data protection, and 516 
communication with end-users about the implementation of such regulations, may build 517 
confidence in the governance framework associated with medical genetic technologies 518 
in general and PN in particular. Consumer confidence may be further enhanced if 519 
providers ensure that personal details and biological data are stored separately. In line 520 
with this, ‘medicalization’ of PN increased discussant concern, because of concerns 521 
about genetic privacy but also because of the requirement to self-sample blood and 522 
cheek cells. As this kind of sampling becomes more commonplace with advances in 523 
medical technologies, some of these concerns may dissipate. However, additional 524 
support, either on-line or by telephone, might reduce existing concerns regarding 525 
sampling. Discussants mentioned that the provision of a 24 hour support service (either 526 
by a telephone hotline or via the internet) would facilitate adherence and maintenance 527 
of PN recommendations, although the financial implications for service delivery would 528 
need to be assessed. Individual differences were identified regarding in the extent to 529 
which discussants thought that total anonymity, remote contact with identifiable health 530 
professionals, or face-to face contact with health professionals would be preferable, 531 
suggesting that different levels of contact may be required to be built in to PN services 532 
by service providers. Payment for services may further consumer confidence and 533 
enhance perceived control over the quality of the PN service provided. It was also 534 
suggested that, having paid for such a service, consumers may be more likely to 535 
provide honest information.  At the same time, expensive fees would act as a barrier to 536 
uptake. The amount which people would be willing to pay for PN could be dependent 537 
on factors such as household income and whether the service can be provided through 538 
existing health providers funded by taxation or insurance and this will be investigated in 539 
future research. 540 
The potential convenience of being able to use the service at any time via the internet 541 
was also raised as a positive aspect of the service, although there may be individual 542 
differences in the extent to which this is regarded as a potential benefit. To maximise 543 
motivation and compliance, PN programmes should be integrated with the individuals’ 544 
lifestyle and tailored to their specific motivations and efficacy. 545 
From these data, it has not been possible to draw comparisons between the different 546 
EU states included in the study. Although it may be considered a strength to have data 547 
from different countries (and identifying as, in this case, agreement in all but attitudes 548 
linked to different national infrastructures), the low number of individuals recruited in 549 
each country (about 15-20 participants) results in difficulties in making direct 550 
comparisons between countries. It is arguable that the exploratory approach adopted 551 
here is invaluable in identifying key determinants of attitude. The analysis of differences 552 
between European countries will allow potential socio-cultural influences on dietary choices 553 
and socio-historical differences in regulatory systems to be identified. 554 
 555 
The results are assumed to be derived from a sample of individuals with relatively low 556 
awareness of PN. The results might have been different in a sample with higher 557 
awareness of PN that included more knowledge about the use of phenotypic and 558 
genotypic data in PN delivery, and so the conclusion cannot be assumed to apply to 559 
the whole population. A further limitation of this research is that the methodology 560 
adopted (mixed focus groups) fails to assess the potential impact that education may 561 
have on knowledge about, and perceptions of perceptions of PN. This issue will be 562 
systematically assessed in the quantitative phase of the research. 563 
 564 
Conclusions 565 
European consumers appear to construe PN in terms of benefit to individual and public 566 
health. Perceived risks are more closely linked to general concerns about privacy and 567 
data security, and are not directly linked to PN. The development of an efficacious, 568 
transparent, and trustworthy regulatory framework for human genetic technologies, 569 
underpinned by the need to optimise human health and consumer protection, may 570 
alleviate concerns. Developing trust in service providers is important, in particular 571 
within the commercial sector. One possible barrier to adoption may be optimistic bias, 572 
suggesting that communication should target those who potentially may benefit from 573 
adopting PN, but who do not perceive that it will benefit them. This might include 574 
younger consumers, as well as those without existing medical conditions. Promotion 575 
might also focus on benefits for health and fitness, whilst simultaneously stressing the 576 
convenience of the online service. Advice should be tailored to align with people’s 577 
lifestyles and preferences, including those related to food choices, motivational factors 578 
and service delivery preferences. Cost may also determine uptake of PN. Cross-579 
cultural and demographic determinants of attitudes towards PN will be investigated in 580 
future research. 581 
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Table 1: Sample description of participants across the focus groups 
Country UK Ireland Greece Netherlands Spain Poland Portugal Germany 
Focus group  1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 
 n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) 
 10 10 8 10 7 8 8 8 8 8 7 7 7 7 7 6 
Male 5  5 3 5 3 4 4 3 4 4 3 3 3 3 4 2 
 (50%) (50%) (38%) (50%) (43%) (50%) (50%) (38%) (50%) (50%) (43%) (43%) (43%) (43%) (57%) (33%) 
Female 5 5 5 5 4 4 4 5 4 4 4 4 4 4 3 4 
 (50%) (50%) (63%) (50%) (57%) (50%) (50%) (63%) (50%) (50%) (57%) (57%) (57%) (57%) (43%) (67%) 
18-25 yrs 3 0 1 0 4 0 1 0 0 0 1 0 1 0 2 0 
 (30%) (0%) (13%) (0%) (57%) (0%) (13%) (0%) (0%) (0%) (14%) (0%) (14%) (0%) (29%) (0%) 
26-30 yrs 2 0 0 0 1 0 0 0 0 0 1 0 1 0 1 1 
 (20%) (0%) (0%) (0%) (14%) (0%) (0%) (0%) (0%) (0%) (14%) (0%) (14%) (0%) (14%) (17%) 
31-39 yrs 2 4 2 1 0 3 1 1 1 1 2 2 1 2 3 1 
 (20%) (40%) (25%) (10%) (0%) (38%) (13%) (13%) (13%) (13%) (29%) (29%) (14%) (29%) (43%) (17%) 
40-49 yrs 2 2 1 3 0 1 3 2 3 3 1 2 2 3 1 3 
 (20%) (20%) (13%) (30%) (0%) (13%) (38%) (25%) (38%) (38%) (14%) (29%) (29%) (43%) (14%) (50%) 
50-59 yrs 1 3 3 4 1 3 1 1 2 1 1 2 2 0 0 1 
 (10%) (30%) (38%) (40%) (14%) (38%) (13%) (13%) (25%) (13%) (14%) (29%) (29%) (0%) (0%) (17%) 
60-65 yrs 0 1 1 0 1 1 2 4 2 3 1 1 1 0 0 0 
 (0%) (10%) (13%) (0%) (14%) (13%) (25%) (50%) (25%) (38%) (14%) (14%) (14%) (0%) (0%) (0%) 
Married 5 9 7 5 1 5 6 7 5 6 6 6 5 6 2 3 
 (50%) (90%) (88%) (50%) (14%) (63%) (75%) (88%) (63%) (75%) (86%) (86%) (71%) (86%) (29%) (50%) 
Single 5 1 1 3 6 3 2 1 3 2 1 1 2 1 5 3 
 (50%) (10%) (13%) (30%) (86%) (38%) (25%) (13%) (38%) (25%) (14%) (14%) (29%) (14%) (71%) (50%) 
Children  12 11 5 8 10 6 11 14 9 8 12 7 6 6 6 5 
 (60%) (60%) (25%) (38%) (72%) (50%) (50%) (87%) (63%) (50%) (100%) (86%) (57%) (57%) (43%) (67%) 
 
Table 2: Focus Group Topic Schedule 
Topic Schedule 
Introduction We’d like to begin the discussion by asking you how much attention you pay to your health? 
We’d also like to know how interested you are in food? 
Awareness and 
Understanding 
Has anyone heard of the term PN? 
We are interested to know what you understand by the term PN? 
PN Definition 
Provided 
‘PN is healthy eating advice that is tailored to suit an individual based on their own personal health 
status, lifestyle and/or genetics’. 
PN Scenarios 1. Lifestyle Data: sex; age; height; weight, food allergies and intolerance; medical history; eating habits; 
and physical activity levels. 
2. Phenotypic Testing: Blood sample for nutrient levels (finger prick test), waist and hip circumference. 
3. Genotypic Testing: DNA sample (via saliva from cheek swab). 
Ethical Issues We are interested in knowing if you have any issues to raise or concerns about how the information from 
the above scenarios might be used and stored?  
We are interested in knowing if you have any issues to raise or concerns about how your personal 
feedback is given or delivered to you? 
We are interested in knowing if you have any issues to raise or concerns about how the feedback 
information might be used by those seeking this service?’ 
Finish Do you think this could be a successful service? Why? 
What would make it successful? 
 
Table 3: Differences in PN Service Provision 
 PN via Existing Healthcare 
Provider 
PN via Commercial On-line Provider 
Personal 
contact 
- Pre-existing relationship 
- Face to face contact 
- Perceived accountability 
 
- Relationship building required 
- Opportunities to use multiple sources of social media to 
connect with PN provider 
- Potential lack of accountability 
Professional 
contact 
- Professional expertise is 
known/inferred, credible and 
trusted 
- Opportunity to use medical 
expertise/supervision 
- Expertise in unknown, lacking in credibility and therefore not 
trusted. 
- Self-efficacy required in taking biological samples 
- Price and service quality 
Privacy - No privacy, but pre-existing 
expertise with personal 
information and biological 
samples e.g. logistics associated 
with biological samples, data 
management 
- Possibility for anonymity 
- Perceived conflicts with commercial objectives and data 
protection 
- Perceived lack of transparency across service delivery supply 
chain 
- Reliance on unreliable/untrustworthy postal service for 
movement of biological samples 
 
